List of Excipients in Branded Drug OMEPRAZOLE DELAYED-RELEASE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Ranbaxy Laboratories Inc	OMEPRAZOLE DELAYED-RELEASE	omeprazole	63304-445	BUTYL ALCOHOL
Ranbaxy Laboratories Inc	OMEPRAZOLE DELAYED-RELEASE	omeprazole	63304-445	CELLULOSE, MICROCRYSTALLINE
Ranbaxy Laboratories Inc	OMEPRAZOLE DELAYED-RELEASE	omeprazole	63304-445	D&C RED NO. 28
Ranbaxy Laboratories Inc	OMEPRAZOLE DELAYED-RELEASE	omeprazole	63304-445	D&C YELLOW NO. 10
Ranbaxy Laboratories Inc	OMEPRAZOLE DELAYED-RELEASE	omeprazole	63304-445	FD&C BLUE NO. 1
Ranbaxy Laboratories Inc	OMEPRAZOLE DELAYED-RELEASE	omeprazole	63304-445	FD&C BLUE NO. 2

Generic Drugs Containing OMEPRAZOLE DELAYED-RELEASE

Company	Ingredient	NDC	Excipient
H-E-B	omeprazole	37808-569	CELLULOSE, MICROCRYSTALLINE
H-E-B	omeprazole	37808-569	CROSPOVIDONE
H-E-B	omeprazole	37808-569	DIMETHICONE
H-E-B	omeprazole	37808-569	FERRIC OXIDE RED
H-E-B	omeprazole	37808-569	GLYCERYL MONOSTEARATE
H-E-B	omeprazole	37808-569	HYDROXYPROPYL CELLULOSE

What are the Most Frequently-Used Excipients in OMEPRAZOLE DELAYED-RELEASE?

# Of NDCs	Excipient
1	ALCOHOL
1	AMMONIA
1	BUTYL ALCOHOL
1	CELLULOSE, MICROCRYSTALLINE
1	CROSPOVIDONE
1	DIMETHICONE

Omeprazole Delayed-Release Excipient Strategy and Commercial Opportunities

Last updated: August 16, 2026

Omeprazole delayed-release is a mature, highly competitive generic and over-the-counter product category. The commercial opportunity is not a new-molecule patent position. It is in differentiated delivery, stability, pediatric usability, lower-cost manufacturing, clean-label excipients, and reformulations that improve adherence or expand nonprescription use.

The core technical requirement is protection of acid-labile omeprazole from gastric degradation until release in the intestine. Most products achieve this with enteric-coated multiparticulates, enteric-coated tablets, or delayed-release capsules containing coated pellets. The strongest development programs will control moisture, coating uniformity, dissolution performance, and dose flexibility while limiting excipient complexity.

What excipients are used in omeprazole delayed-release products?

Omeprazole delayed-release products generally use a multi-layer pellet or tablet system. The active ingredient is exposed to an alkaline microenvironment, separated from acidic gastric fluid, and released after the dosage form reaches a higher-pH intestinal environment.

Typical excipient architecture

Formulation function	Common excipient classes	Commercial purpose
Alkaline stabilizer	Magnesium oxide, magnesium carbonate, sodium bicarbonate	Protects omeprazole from acid degradation
Pellet core	Sucrose spheres, microcrystalline cellulose, starch	Provides a uniform substrate for drug layering
Binder	Hypromellose, povidone	Supports uniform drug deposition
Surfactant or wetting agent	Sodium lauryl sulfate, polysorbates	Improves coating and drug-layer uniformity
Separation layer	Hypromellose, polymeric film coat	Prevents interaction between omeprazole and enteric polymer
Enteric coating	Methacrylic acid copolymers, cellulose acetate phthalate, hypromellose phthalate	Delays release until intestinal pH
Plasticizer	Triethyl citrate, polyethylene glycol	Improves film flexibility and reduces cracking
Anti-tacking agent	Talc, colloidal silicon dioxide	Prevents pellet agglomeration
Capsule shell	Gelatin or hypromellose	Contains coated pellets
Colorant or opacifier	Titanium dioxide, iron oxides, approved dyes	Product identification and light protection

FDA-approved omeprazole delayed-release capsules commonly contain sugar spheres, hypromellose, povidone, sodium lauryl sulfate, methacrylic acid copolymers, triethyl citrate, talc, and colorants. The exact composition differs by manufacturer and strength. FDA labeling and the Inactive Ingredient Database should be reviewed at the product level before regulatory or formulation decisions are made (FDA, 2024a; DailyMed, 2024a).

Why alkaline excipients are commercially important

Omeprazole is acid labile. An alkaline excipient in the drug layer or pellet core can raise local pH and improve chemical stability. Magnesium oxide is widely used in delayed-release formulations because it provides alkalinity without requiring a complex delivery system.

The trade-off is manufacturability. Alkaline materials can alter polymer-film behavior, increase formulation variability, and affect dissolution if their distribution is uneven. Particle size, surface area, water content, and mixing time require tighter control than in conventional immediate-release tablets.

Sodium bicarbonate has a stronger commercial role in liquid or suspension products. It can provide an alkaline vehicle and improve short-term stability, but bicarbonate systems introduce taste, gas evolution, packaging, and moisture-management considerations.

What formulations are protected by omeprazole delayed-release technology?

The main formulation types are delayed-release capsules, enteric-coated tablets, orally disintegrating tablets, oral suspensions, and multiparticulate sprinkle products.

Delayed-release capsules

Capsules containing enteric-coated pellets remain the dominant generic design. They offer:

• Established regulatory precedent.
• Dose strengths of 10 mg, 20 mg, and 40 mg.
• Compatibility with pellet manufacturing.
• Potential for capsule opening and sprinkling in selected patient populations.
• Broad access to contract manufacturing capacity.

Their principal limitations are pellet-coating complexity, capsule-filling cost, moisture sensitivity, and the need to demonstrate consistent dissolution across the full shelf life.

Delayed-release tablets and MUPS products

Multiple-unit pellet system, or MUPS, tablets place enteric-coated pellets inside a compressed tablet matrix. MUPS products can improve brand differentiation, portability, and swallowing convenience. They also allow a tablet presentation in markets where capsules are less preferred.

Compression creates technical risk. Excessive force can damage the enteric coat and cause premature release. Formulators must balance tablet hardness, friability, disintegration, pellet integrity, and acid-stage dissolution.

MUPS technology can support line extensions, but the commercial value depends on whether the dosage form offers a clear patient or payer benefit. A tablet without a meaningful usability advantage may face substitution by lower-cost capsules.

Oral suspensions and packets

Omeprazole oral suspension products target pediatric patients, patients with feeding tubes, and adults who cannot swallow solid dosage forms. FDA-approved products use a separate alkaline vehicle or a powder-for-suspension system. Konvomep, for example, combines omeprazole and sodium bicarbonate in an oral suspension presentation, while other products use delayed-release granules or packets (DailyMed, 2024b).

This segment has higher differentiation potential because reconstitution, dosing accuracy, taste, tube compatibility, and storage requirements create barriers beyond ordinary capsule manufacture.

Orally disintegrating and sprinkle products

Orally disintegrating tablets and sprinkle formulations can improve administration in children and older adults. They require careful control of:

• Particle size and mouthfeel.
• Enteric-coat integrity after dispersion.
• Palatability.
• Dose uniformity across partial doses.
• Compatibility with applesauce, juice, or feeding tubes.

Products that permit capsule opening or sprinkling must specify administration conditions. Food vehicles, residence time, and chewing can affect the enteric coating and dissolution profile.

How should an excipient strategy be designed for omeprazole?

A strong excipient strategy should start with the release mechanism rather than with a generic excipient substitution exercise.

1. Establish the alkaline microenvironment

The formulation should maintain omeprazole stability during granulation, coating, encapsulation, and storage. Magnesium oxide is practical for solid multiparticulates. Sodium bicarbonate is more suitable for selected liquid or powder systems.

Development teams should assess:

• Local pH around the drug.
• Omeprazole degradation products.
• Moisture uptake.
• Residual solvent.
• Interaction with enteric polymers.
• Stability after capsule opening or reconstitution.

2. Separate the drug layer from the enteric polymer

A subcoat is often necessary. Direct contact between an alkaline drug layer and an enteric polymer can affect film formation and dissolution. Hypromellose or another neutral barrier polymer can provide separation and improve pellet robustness.

This layer adds processing time and material cost. It can still be commercially valuable if it reduces batch failures, improves dissolution consistency, or extends shelf life.

3. Select the enteric polymer around the target profile

Methacrylic acid copolymers provide well-established pH-dependent release. The choice of polymer grade affects the onset of dissolution, coating weight, aqueous dispersion behavior, and regulatory precedent.

Key variables include:

• Polymer equivalent weight and acid content.
• Coating weight gain.
• Plasticizer level.
• Talc concentration.
• Inlet and product temperature.
• Spray rate.
• Drying and curing conditions.

The commercial objective is not simply to delay release. It is to achieve reproducible acid resistance followed by rapid intestinal release.

4. Control water activity

Moisture is a major degradation risk. Packaging can be as important as the excipient formula. High-barrier bottles, desiccants, blister packs, and unit-dose sachets may be required depending on the dosage form.

A low-cost formulation with poor moisture protection can generate higher total cost through shorter shelf life, recalls, or conservative expiration dating. Stability data should support the selected container-closure system.

5. Minimize unnecessary excipient complexity

A simpler formula can reduce:

• Supplier qualification burden.
• Batch-to-batch variability.
• Labeling complexity.
• Allergen and intolerance concerns.
• Manufacturing cost.
• Change-control exposure.

The constraint is that removing an excipient may affect pellet adhesion, enteric integrity, dissolution, or stability. A clean-label strategy must be validated against performance, not pursued as a marketing claim alone.

What commercial opportunities exist in omeprazole delayed-release?

Pediatric and geriatric formulations

The strongest formulation opportunity is administration flexibility. Pediatric patients and older adults frequently have difficulty swallowing conventional capsules. Liquid suspensions, sprinkle products, and low-volume concentrated presentations can command higher pricing than standard generic capsules.

Commercial differentiation can come from:

• Ready-to-use suspension.
• Longer in-use stability.
• Improved taste masking.
• Accurate oral-syringe dosing.
• Feeding-tube compatibility.
• Reduced reconstitution steps.
• Lower sodium content where clinically relevant.

Pediatric omeprazole products must address dosing by age or weight, device compatibility, microbial control, and caregiver usability.

Hospital and institutional products

Hospitals and long-term-care providers value dosage forms that reduce preparation time. Unit-dose packets, tube-compatible formulations, and stable suspensions can support institutional contracting.

A formulation that avoids compounding from capsules may have a practical advantage in hospitals, particularly where pharmacy labor and administration safety are major cost drivers.

OTC and private-label products

Omeprazole 20 mg delayed-release is a mature OTC category in the United States. The FDA switched Prilosec 20 mg to nonprescription status in 2003, and multiple private-label and store-brand products now compete on price, count size, packaging, and retailer placement (FDA, 2003).

The most realistic OTC opportunities are:

• Retailer-specific private-label supply.
• Smaller count packages.
• Multi-month value packs.
• Blister and unit-dose packaging.
• Vegetarian capsule shells.
• Products positioned around simple ingredient profiles.
• Combination packages with antacids or other gastrointestinal products.

A new excipient system alone will rarely support a premium OTC price. The commercial case must connect the formulation to shelf life, ease of use, packaging efficiency, or a defensible label claim.

Specialty pharmacy and adherence products

A capsule that can be opened and sprinkled without compromising delayed release may improve adherence in patients with swallowing difficulties. Packaging with dose reminders or calendarized units can support adherence programs, although these features are usually easier to protect through packaging or design patents than through a core pharmaceutical composition patent.

Global markets

Geographic opportunity is shaped by local registration status, prescription-to-OTC classification, manufacturing economics, and excipient acceptability. Enteric-coated pellets are attractive in markets with established generic manufacturing infrastructure. Liquid and pediatric presentations may be more differentiated in markets where hospital compounding remains common.

The main regional barriers are:

• Different allowable colorants.
• Local pharmacopeial requirements.
• Country-specific excipient labeling.
• Requirements for bioequivalence or comparative dissolution.
• Local manufacturing or serialization rules.
• Price controls and tender procurement.

What patent and regulatory rights protect omeprazole delayed-release?

Omeprazole is an old small-molecule proton pump inhibitor. The original product patents and exclusivity periods have expired. There is no biosimilar pathway because omeprazole is a chemically synthesized small molecule, not a biologic.

U.S. regulatory status

Issue	Current commercial implication
New chemical entity exclusivity	Expired
Original Prilosec patents	Expired
Generic ANDA pathway	Established
OTC omeprazole	Established for qualifying products
Orange Book listings	Product-specific; remaining listings must be reviewed by reference product and dosage form
Paragraph IV risk	Relevant mainly to new listed formulations or combination products
Biosimilar risk	Not applicable
Generic competition	High
Main regulatory barrier	Bioequivalence, dissolution, stability, and manufacturing consistency

FDA’s Orange Book lists approved drug products and patent information for listed products. Because omeprazole has multiple reference products, dosage forms, strengths, and formulations, Orange Book analysis must be performed at the specific product level rather than by active ingredient alone (FDA, 2024b).

Paragraph IV challenges

For conventional omeprazole delayed-release capsules, Paragraph IV litigation is not the central market risk because the foundational patent estate has expired and numerous generic products are already approved. Paragraph IV exposure can still arise for:

• New oral suspension products.
• Fixed-dose combinations.
• New delivery systems.
• Pediatric formulations.
• Novel dosage forms with active Orange Book patents.
• Formulations with method-of-use claims.

The practical question is whether a new product has a listed patent that is both enforceable and commercially relevant. A formulation patent with narrow claims may not prevent capsule or tablet substitution if the market has multiple non-infringing alternatives.

How strong is the omeprazole delayed-release patent estate?

The core patent estate is weak as a barrier to standard generic entry because the original compound and conventional delayed-release technologies are long established. The stronger intellectual-property positions are likely to involve narrow improvements.

Potentially defensible IP areas

• Specific pellet architecture.
• Defined alkaline drug-layer composition.
• Particular enteric-polymer combinations.
• Low-moisture formulations with extended stability.
• Ready-to-use suspension systems.
• Taste-masked pediatric products.
• Tube-compatible delivery systems.
• Manufacturing processes that reduce coating defects.
• Specific combinations with sodium bicarbonate or other actives.
• Packaging systems tied to stability performance.

Patent strength depends on claim breadth, enablement, prior art, freedom to operate, and whether competitors can design around the claimed excipient ratios or process parameters.

A patent directed only to a common enteric polymer or ordinary magnesium-oxide stabilization strategy is likely to face substantial prior-art pressure. A patent covering a narrow but commercially important performance advantage can still support licensing, but its value depends on whether the market pays for the advantage.

Which companies are challenging or competing in omeprazole delayed-release?

The market includes large generic manufacturers, branded-generic suppliers, OTC retailers, and specialized oral-liquid developers. Major participants have included AstraZeneca through Prilosec and Prilosec OTC, as well as generic manufacturers such as Teva, Viatris, Dr. Reddy's, Sandoz, Perrigo, ANI Pharmaceuticals, and private-label suppliers. Product availability varies by country and time.

Competition is concentrated in three tiers:

1. Commodity delayed-release capsules, where price and supply reliability dominate.
2. OTC products, where retailer access, packaging, and marketing determine share.
3. Differentiated suspensions and pediatric products, where formulation and regulatory execution create more defensible margins.

The most attractive licensing targets are companies with validated enteric-pellet platforms, pediatric liquid expertise, high-barrier packaging capability, or established retail and institutional channels.

What generic entry risks exist for omeprazole delayed-release?

The primary risk is price erosion rather than patent litigation. Standard capsule products face multiple approved competitors and limited switching costs.

Generic launch scenarios

Scenario	Likely market effect
New standard 20 mg capsule	Rapid price competition and limited differentiation
New private-label capsule	Retail share shift with low sustainable margin
MUPS tablet	Moderate differentiation if swallowing or packaging benefit is clear
Ready-to-use suspension	Higher price potential and lower direct competition
Pediatric sprinkle product	Specialist opportunity with regulatory and usability barriers
Combination product	More complex patent, clinical, and labeling analysis
Improved-stability product	Potential institutional or global-market value

Manufacturing risk is often more important than patent risk. Coating defects, premature release, potency loss, and dissolution drift can cause regulatory observations or product shortages. A manufacturer with reliable fluid-bed coating, in-process testing, and moisture-control systems can outperform a lower-cost competitor.

How does omeprazole compare with other proton pump inhibitors?

Product	Common delayed-release challenge	Excipient opportunity
Omeprazole	Acid instability and intense generic competition	Pediatric liquids, sprinkle products, low-cost pellets
Esomeprazole	Similar acid-labile chemistry, greater brand and formulation differentiation	MUPS and premium dosage forms
Lansoprazole	Acid-labile API and multiple pediatric presentations	Orally disintegrating and suspension formats
Pantoprazole	Delayed-release stability and institutional use	Hospital-focused tablets and injectable alternatives
Rabeprazole	Acid-labile API with differentiated release requirements	Specialty formulations and regional products

Omeprazole has the broadest commodity exposure but also the largest installed market and the deepest manufacturing base. Esomeprazole and lansoprazole can offer stronger premium positioning in selected formulations, while omeprazole is more suitable for scale, private-label supply, and cost-efficient line extensions.

What licensing deals and commercial partnerships are relevant?

The most commercially relevant deals are likely to involve:

• Contract development and manufacturing of enteric pellets.
• Licensing of oral suspension technology.
• Private-label OTC supply agreements.
• Pediatric product commercialization.
• Regional distribution rights.
• Packaging and device partnerships.
• Co-development of fixed-dose combinations.

A licensing transaction should value more than the active ingredient. Key diligence items include ownership of formulation patents, freedom to operate around enteric polymers, regulatory approval status, manufacturing transferability, stability data, supplier dependence, and existing customer contracts.

For standard capsules, royalty economics are likely to be constrained by generic pricing. Specialized liquid, pediatric, and institutional products offer a stronger basis for milestone and royalty structures.

Key Takeaways

• Omeprazole delayed-release is a mature generic and OTC market with limited core patent protection.
• The central formulation problem is protecting acid-labile omeprazole until intestinal release.
• Magnesium oxide, sodium bicarbonate, hypromellose, methacrylic acid copolymers, triethyl citrate, talc, and sugar spheres are common excipient components.
• Enteric-coated multiparticulates remain the most established platform.
• Ready-to-use suspensions, pediatric sprinkle products, tube-compatible formulations, and MUPS tablets offer the clearest differentiation.
• Moisture control, coating integrity, dissolution, and manufacturing consistency are major commercial barriers.
• Paragraph IV litigation is less important for conventional omeprazole capsules than for new formulations or combination products.
• Biosimilar competition does not apply.
• Standard capsules are exposed to rapid generic price erosion.
• The strongest commercial opportunity is a formulation with a measurable administration, stability, packaging, or institutional-use advantage.

FAQs

Can omeprazole delayed-release capsules be reformulated without enteric coating?

No. Omeprazole requires protection from gastric acid. A formulation without an effective delayed-release mechanism would generally risk degradation before intestinal absorption and would require a different protective delivery strategy.

Is magnesium oxide necessary in every omeprazole delayed-release formulation?

No. Magnesium oxide is common, but other alkaline systems can be used. The substitute must maintain chemical stability, preserve enteric performance, and satisfy regulatory requirements.

Can omeprazole delayed-release be sold as a liquid?

Yes. Oral suspensions and powder-for-suspension products are established dosage forms. Their principal development challenges are stability, taste, reconstitution, dosing accuracy, microbial control, and feeding-tube compatibility.

Does a new enteric polymer create patent protection for omeprazole?

Not automatically. A formulation patent requires novel and non-obvious claim scope. Common enteric polymers and routine coating methods may face substantial prior art. Protection is stronger when the polymer system is tied to a defined performance or manufacturing advantage.

What is the best commercial dosage form for a new omeprazole product?

For volume, delayed-release capsules are the most practical. For differentiation and pricing, ready-to-use suspensions, pediatric sprinkle products, and tube-compatible formulations generally offer better opportunities, provided they demonstrate clear usability or stability benefits.

References

1. DailyMed. (2024a). Omeprazole delayed-release capsules: Prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. DailyMed. (2024b). Konvomep: Omeprazole and sodium bicarbonate for oral suspension. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2003). FDA approves Prilosec OTC for frequent heartburn. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2024a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

5. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

6. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

7. U.S. Food and Drug Administration. (2024c). Approved drug product labels and prescribing information. https://www.accessdata.fda.gov/iyanas/